Anoro Ellipta is used once-daily to treat chronic obstructive pulmonary disease (COPD) over the long-term. Anoro combines two inhaled COPD bronchodilator agents, umeclidinium bromide, a long-acting muscarinic antagonist and vilanterol, a long-acting beta2-agonist. Anoro, from GlaxoSmithKline, is administered using the Ellipta inhaler.

The product label does not state that you rinse your mouth after using Anoro, because Anoro does not contain a corticosteroid medicine. You should rinse your mouth after you inhale a corticosteroid (such as fluticasone) to help prevent mouth or throat fungal infections like thrush, but this is not a concern with Anoro. You may experience a mild sore throat when using Anoro.

This medication works by work by relaxing muscles in the airways to improve breathing and to reduce the number of flare-ups (the worsening of your COPD symptoms). Anoro Ellipta is for use only in people with COPD and should not be used to treat asthma or as a rescue (quick-acting) inhaler such as albuterol.